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Effect of waiting time on renal transplant outcome. doubled over the last decade, the number of potential
Background. Numerous factors are known to impact on pa- donor kidneys has not shown a substantial growth [10].
tient survival after renal transplantation. Recent studies have As a consequence of these two factors, the waiting timeconfirmed a survival advantage for renal transplant patients
to receive a renal allograft has been increasing [10].over those waiting on dialysis. We aimed to investigate the
There is some evidence that patients who receive ahypothesis that longer waiting times are more deleterious than
shorter waiting times, that is, to detect a “dose effect” for preemptive renal transplant have a survival advantage
waiting time. as opposed to patients who receive a renal transplant
Methods. We analyzed 73,103 primary adult renal trans- after a period of maintenance dialysis therapy [11, 12].plants registered at the United States Renal Data System Reg-
Because of the selection bias inherent in the choice ofistry from 1988 to 1997 for the primary endpoints of death
patients for preemptive transplant, it is difficult to discernwith functioning graft and death-censored graft failure by Cox
proportional hazard models. All models were corrected for from these studies whether waiting time on dialysis per
donor and recipient demographics and other factors known to se is a risk factor for poor survival post-transplant. In
affect outcome after kidney transplantation. addition, these analyses preclude the ability to test theResults. A longer waiting time on dialysis is a significant risk
hypothesis that longer waiting times are more deleteri-factor for death-censored graft survival and patient death with
ous than shorter waiting times, that is, detect a “dosefunctioning graft after renal transplantation (P , 0.001 each).
Relative to preemptive transplants, waiting times of 6 to 12 effect” for waiting time.
months, 12 to 24 months, 24 to 36, 36 to 48, and over 48 months A retrospective, single-center study by Cosio et al
confer a 21, 28, 41, 53, and 72% increase in mortality risk after analyzing 523 patients concluded that longer waiting pe-transplantation, respectively. Relative to preemptive trans-
riods were associated with an increased mortality post-plants, waiting times of 0 to 6 months, 6 to 12 months, 12 to
transplant [13]. Conversely, a larger study by Arend et24 months, and over 24 months confer a 17, 37, 55, and 68%
increase in risk for death-censored graft loss after transplanta- al in 1002 renal transplant recipients did not find any
tion, respectively. effect of length of pretransplant dialysis on patient sur-
Conclusions. Longer waiting times on dialysis negatively im-
vival [14]. Neither of these studies detected any correla-pact on post-transplant graft and patient survival. These data
tion of shorter waiting time on dialysis with better death-strongly support the hypothesis that patients who reach end-
stage renal disease should receive a renal transplant as early censored graft survival.
as possible in order to enhance their chances of long-term Given the improved survival of ESRD patients with
survival. transplantation compared with dialysis, it is not unrea-
sonable to hypothesize that patients on dialysis may suf-
fer accelerated adverse vascular and metabolic effects
Transplantation has been shown to improve survival that might predispose them to a poorer outcome once
when compared with maintenance dialysis for patients they receive their transplant. In fact, several studies have
with end-stage renal disease (ESRD) [1–6]. In addition, documented an acceleration of atherosclerosis in dialysis
renal transplantation is a cost-effective modality that patients [15–17]. In addition, dialysis is associated with
offers improved quality of life for patients with ESRD an increased accumulation of a variety of proinflamma-
[7–9]. While the incidence of treated ESRD has almost tory and proatherogenic factors that could potentially
adversely affect both patient and graft survival post-
transplantation [18–30]. Studies to date have yet to yieldKey words: graft survival, mortality and transplantation, post-trans-
plant death, end-stage renal disease, dialysis. a conclusive answer to these unresolved issues. Thus, we
undertook an analysis of the United States Renal DataReceived for publication January 25, 2000
System Registry (USRDS) to assess the impact of wait-and in revised form March 15, 2000
Accepted for publication March 20, 2000 ing time on post-transplant graft survival with and with-
out censoring at death and on patient survival.Ó 2000 by the International Society of Nephrology
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METHODS RESULTS
DemographicsThis study was based on data collected by the U.S.
Renal Transplant Scientific Registry and supplemented A total of 73,103 patients were eligible for the analysis.
with ESRD data in the U.S. Renal Data System. The The characteristics of the patient population are dis-
study sample consisted of patients who underwent soli- played in the first two columns of Table 1.
tary primary (multiorgan and secondary, transplants
Death-censored graft survivalwere excluded from the analysis) renal transplantation
The results from the Cox proportional hazard modelbetween October 1, 1988, and June 30, 1997. Patients
are shown in Table 1. Increasing waiting time on dialysiswere followed from transplant date until graft loss or
was a significant risk factor for death-censored graft lossdeath or until the study end date of June 30, 1998. Wait-
after renal transplantation (P , 0.001). Being on dialysising time on dialysis was calculated from the start of
for up to six months prior to transplantation conferredmaintenance dialysis treatment to transplant date.
a 17% increased risk for death-censored graft loss asPrimary study endpoints included patient death with
compared with preemptive renal transplantation whenfunctioning graft and death-censored graft failure. As an
adjusted for all factors described in the Methods section.additional endpoint, we evaluated chronic renal allograft
Dialysis treatment for 6 to 12, 12 to 24, and 24 to 36failure, defined as graft loss after six months post-trans-
months prior to renal transplantation conferred a 37,plant, censored for patient death or graft loss secondary
55, and 68% higher risk for death-censored graft loss,to acute rejection, graft thrombosis, infection, surgical
respectively. Beyond 36 months of dialysis, there re-complications, or recurrent disease.
mained a significantly increased risk of death censored
The impact of waiting time on dialysis prior to trans-
graft loss as opposed to preemptive transplantation (P ,
plantation on these primary endpoints was analyzed both 0.001); however, the relative increase beyond 36 months
as a continuous variable and as a categorical variable. from 68% to 70% to 74% was small and not statistically
Cox proportional hazard regression was used to esti- significant.
mate the independent effect of waiting time on the pri- Other significant risk factors for death-censored graft
mary study endpoints while controlling for relevant risk loss were higher donor age (P , 0.001), African Ameri-
factors. To account for a potentially dominant era effect, can recipient race (P , 0.001), African American donor
the year of transplantation was included as an explana- race (P , 0.001), higher HLA mismatching (P , 0.001),
tory covariate in the Cox proportional hazard analysis. HTN (P , 0.001), and diabetes (P , 0.001) as the cause
Other potential confounding variables studied were of ESRD and increasing cold ischemia time (P , 0.001).
cyclosporine versus tacrolimus treatment; induction ver- Significant protective factors from death-censored
sus no induction treatment; recipient age at transplanta- graft loss were a more recent era of transplantation (P ,
0.001), mycophenolate mofetil as opposed to azathio-tion; donor age; donor and recipient race, gender, and
prine therapy (P , 0.001), and living versus cadavericcytomegalovirus (CMV) IgG antibody status; primary
donation (P , 0.001).cause of ESRD; donor source (cadaveric vs. living); cold
Figure 1 shows the Cox proportional hazard estimatedand warm ischemia times; human lymphocyte antigen
death-censored graft survival stratified by waiting time(HLA) mismatch; presensitization (PRA); and delayed
on dialysis. With increasing waiting time on dialysis, thegraft function. Delayed graft function was defined as a
estimated censored graft survival was significantly worseneed for one or more dialysis treatments in the first post-
(P , 0.001).transplant week. Only significant variables (P , 0.05)
As shown in Figure 2, there was a significant increasewere reported in the tables.
in the relative risk for censored graft loss with increasing
To evaluate the impact of waiting time separately by
duration of pretransplant dialysis for each of the three
cause of ESRD, we built an interaction term between major ESRD disease groups: GN, HTN, and DM.
these two factors into the Cox proportional hazard Analyzing the data using a more restricted definition
model. In this subanalysis, only a subset of the original of graft survival, defined as chronic renal allograft failure
patient pool was selected: Only patients within the three in the methods, we obtained similar results (data not
major primary disease groups [glomerulonephritis (GN), shown).
hypertension (HTN), and diabetes mellitus (DM)] were
Patient survivalanalyzed.
A probability of type 1 error (a) 5 0.05 was considered When adjusting for all factors described in the Meth-
to be the threshold of statistical significance. All statisti- ods section, increasing waiting time on dialysis was also a
cal analyses were performed using SPSS software (ver- significant risk factor for patient death with a functioning
graft after renal transplantation (P , 0.001; Table 2).sion 7.0 for Windows 95; SPSS, Inc., Chicago, IL, USA).
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Table 1. Cox proportional hazard model for the relative risk (RR) of death-censored graft loss (N 5 73,103)
Demographics
Variable (reference group) %/mean6SD RR 95% CI P value
Donor age (per 1 year) 33.9615.5 1.01 1.011–1.013 ,0.001
Year of transplant (per year) 0.96 0.95–0.967 ,0.001
Recipient race (White) 70.7% ,0.001a
African American 22.8% 1.70 1.63–1.76 ,0.001
Other 6.5% 0.90 0.84–0.97 0.01
Donor race (White) 84.4% ,0.001
African American 11.1% 1.16 1.11–1.28 ,0.001
Other 2.7% 0.99 0.85–1.15 0.88
HLA mismatch
Per 1 AB 2.7661.27 1.09 1.07–1.10 ,0.001
Per 1 DR 1.3460.75 1.09 1.07–1.10 ,0.001
% PRA 5.0615.1 1.01 1.006–1.033 0.004
Primary diagnosis (GN) 23.0% ,0.001a
Hypertension 17.4% 1.29 1.24–1.36 ,0.001
Diabetes 26.6% 1.18 1.13–1.24 ,0.001
Mycophenolate mofetil (azathioprine) 12.0% 0.66 0.60–0.72 ,0.001
Living donation (cadaveric donor) 24.8% 0.64 0.60–0.68 ,0.001
Cold ischemia (per 1 hour) 17.3612.5 1.01 1.001–1.011 ,0.001
Time on dialysis prior to tx (preemptive) 15.0% ,0.001a
Up to 6 months 11.7% 1.17 1.08–1.26 0.001
6 to 12 months 16.0% 1.37 1.28–1.47 ,0.001
12 to 24 months 24.4% 1.55 1.45–1.65 ,0.001
24 to 36 months 14.2% 1.68 1.58–1.81 ,0.001
36 to 48 months 7.8% 1.70 1.57–1.84 ,0.001
More than 48 months 10.9% 1.74 1.62–1.86 ,0.001
a Overall significance of the variable
Fig. 1. Death-censored graft survival esti-
mated by Cox proportional hazard analysis.
Maintenance dialysis therapy for up to six months prior to 36, 36 to 48, and above 48 months prior to renal
transplantation conferred a 21, 28, 41, 53, and 72% in-to transplantation did not confer an increased risk for
patient death after transplantation as compared with pre- creased adjusted risk for censored graft loss, respectively.
Other significant risk factors for patient death includedemptive renal transplantation. However, more than six
months of dialysis treatment prior to renal transplanta- increasing donor and recipient age (P , 0.001), HTN
(P , 0.001), and diabetes (P , 0.001) as the cause oftion conferred a significant and progressive increase in
the relative risk for patient death after transplantation ESRD as opposed to GN and longer cold ischemia time
(P , 0.001). Significant protective factors were the more(P , 0.001). Dialysis treatment for 6 to 12, 12 to 24, 24
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Fig. 2. Relative risk for death-censored graft
loss by primary disease.
Table 2. Cox proportional hazard model for the relative risk (RR) of death with functioning graft
Variable (reference group) (RR) 95% CI P value
Donor age (per 1 year) 1.001 1.003–1.006 ,0.001
Recipient age (per 1 year) 1.04 1.03–1.044 ,0.001
Year of transplant (per year) 0.94 0.93–0.95 ,0.001
Primary diagnosis (GN) ,0.001a
Hypertension 1.23 1.12–1.34 ,0.001
Diabetes 1.99 1.85–2.14 ,0.001
Mycophenolate mofetil (azathioprine) 0.48 0.41–0.56 ,0.001
Living donation (cadaveric donor) 0.70 0.63–0.77 ,0.001
Cold ischemia (per 1 hour) 1.003 1.0004–1.005 ,0.001
Time on dialysis prior to tx (preemptive) ,0.001a
Up to 6 months 1.001 0.89–1.12 NS
6 to 12 months 1.21 1.09–1.33 ,0.001
12 to 24 months 1.28 1.16–1.40 ,0.001
24 to 36 months 1.41 1.26–1.55 ,0.001
36 to 48 months 1.53 1.36–1.72 ,0.001
More than 48 months 1.72 1.55–1.91 ,0.001
a Overall significance of the variable
recent era of transplantation (P , 0.001), mycophenolate with poorer outcomes was observed independently of
mofetil therapy as opposed to azathioprine (P , 0.001), recipient age according to analyses of interactions be-
and living donation (P , 0.001). tween age and waiting time.
The Cox proportional hazard estimated patient sur-
vival is shown in Figure 3. The estimated eight-year pa-
DISCUSSIONtient survival was significantly better among patients who
The results of our study demonstrate that waiting timeexperienced shorter periods of pretransplant dialysis
on dialysis is a strong risk factor for decreased patient(P , 0.001).
survival as well as decreased death-censored graft sur-As shown in Figure 4, there was a significant increase
vival following renal transplantation. This effect was in-in the relative risk for patient death with increasing time
dependent of all other factors in the model (includingof pretransplant dialysis for each of the three major
recipient age, race, original disease, and donor character-ESRD disease groups: GN, HTN, and DM.
istics) and likely reflects a true negative effect of waitingThe effect of waiting time on dialysis on both patient
time on dialysis. This negative effect held equally trueand graft survival was also confirmed when living donor
for patients with systemic diseases (for example, DM)kidney recipients and cadaver donor kidney recipients
as well as for patients with renal specific disease (forwere analyzed separately.
In addition, the association of longer waiting times example, GN) and thus is unlikely to be due to a longer
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Fig. 3. Patient survival estimated by Cox pro-
portional hazard analysis.
Fig. 4.. Relative risk for death with function-
ing graft by primary disease.
exposure to a systemic process. In addition, the negative analysis suggests that waiting time on dialysis also confers
an increased relative risk for the development of chroniceffect of waiting time appeared to be linear, with longer
waiting periods conferring a greater relative risk of poor allograft nephropathy.
The reason that waiting time is associated with anoutcome.
It is interesting to note that not only did waiting time increased risk of patient death and chronic allograft fail-
ure can only be inferred from the data we have presented.incur a greater relative risk for patient death following
renal transplantation, but also conferred a similarly One possible explanation may be that while dialysis is
clearly a life-saving therapy, it is a less than perfect renalstrong negative risk factor for death-censored graft sur-
vival. In fact, when patients with death-censored graft replacement modality, and thus, the longer one waits on
dialysis, the longer that patient is exposed to the chronicsurvival were further subdivided to exclude those pa-
tients with surgical problems, infections, acute rejection, effects of end-stage renal failure and dialysis. It is well
documented that patients on dialysis have alterations inand recurrent disease, a similar trend emerged. This sub-
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ity of life in renal transplantation: A prospective study. Trans-the concentration of a number of substances (for exam-
plantation 54:656–660, 1992
ple, homocysteine, advanced glycosylation end products, 9. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong
C, Muirhead N: A study of the quality of life and cost-utility ofand lipoproteins) [18–30] that may predispose these pa-
renal transplantation. Kidney Int 50:235–242, 1996tients to both cardiovascular and renal allograft vascular
10. US Renal Data System: USRDS 1999 Annual Data Report.
damages. In addition, poor nutrition, the chronic in- Bethesda, The National Institute of Health, National Institute of
Diabetes and Digestive and Kidney Diseases, April 1999flammatory state, altered immunologic function, and in-
11. Roake JA, Cahill AP, Gray CM, Gray DW, Morris PJ: Preemp-adequate clearance that often accompanies ESRD pa-
tive cadaveric renal transplantation: Clinical outcome. Transplanta-
tients on dialysis [31–35] may predispose these patients tion 62:1411–1416, 1996
12. Asderakis A, Augustine T, Dyer P, Short C, Campbell B, Par-to poorer tolerance to the immunosuppressive agents
rott NR, Johnson RW: Pre-emptive kidney transplantation: Theafter transplantation. Therefore, long-term dialysis pa-
attractive alternative. Nephrol Dial Transplant 13:1799–1803, 1998
tients may be at a disadvantaged state when finally re- 13. Cosio FG, Alamir A, Yim S, Pesavento TE, Falkenhain ME,
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guson RM: Patient survival after renal transplantation. I. TheIn summary, waiting time emerges as a strong indepen-
impact of dialysis pre-transplant. Kidney Int 53:767–772, 1998
dent risk factor for increased patient mortality and in- 14. Arend SM, Mallat MJ, Westendorp RJ, Van Der Woude FJ,
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15. Huysmans K, Lins RL, Daelemans R, Zachee P, De Broe ME:
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disease. J Nephrol 11:185–195, 1998of these negative outcomes. Furthermore, this effect is
16. London GM, Drueke TB: Atherosclerosis and arteriosclerosis inequally important among the three major disease groups
chronic renal failure. Kidney Int 51:1678–1695, 1997
that cause ESRD. The etiology of this increased risk 17. Wheeler DC: Cardiovascular disease in patients with chronic renal
failure. Lancet 348:1673–1674, 1996may be related to a poorer general condition of patients
18. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C:who wait longer for a transplant as well as dialysis-related
Inflammation enhances cardiovascular risk and mortality in hemo-
changes in the recipient milieu, which hastens both car- dialysis patients. Kidney Int 55:648–658, 1999
19. Lowrie EG: Acute-phase inflammatory process contributes to mal-diac and graft arteriosclerosis.
nutrition, anemia, and possibly other abnormalities in dialysis pa-Our results provide strong support for the hypothesis tients. Am J Kidney Dis 32(Suppl):S105–S112, 1998
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